| __timestamp | Catalyst Pharmaceuticals, Inc. | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 10117774 | 8494000000 |
| Thursday, January 1, 2015 | 11801342 | 9046000000 |
| Friday, January 1, 2016 | 11369941 | 9095000000 |
| Sunday, January 1, 2017 | 11375237 | 10554000000 |
| Monday, January 1, 2018 | 19919204 | 10775000000 |
| Tuesday, January 1, 2019 | 18842752 | 11355000000 |
| Wednesday, January 1, 2020 | 16496715 | 12340000000 |
| Friday, January 1, 2021 | 16936000 | 14277000000 |
| Saturday, January 1, 2022 | 19789000 | 14135000000 |
| Sunday, January 1, 2023 | 93150000 | 15048000000 |
| Monday, January 1, 2024 | 17232000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, Johnson & Johnson has consistently outpaced Catalyst Pharmaceuticals in R&D spending. In 2023, Johnson & Johnson's R&D expenses reached approximately $15 billion, marking a 77% increase from 2014. In contrast, Catalyst Pharmaceuticals saw a significant surge in 2023, with R&D expenses jumping to $93 million, a remarkable 820% increase from 2014. This disparity highlights Johnson & Johnson's robust commitment to innovation, while Catalyst Pharmaceuticals is rapidly scaling its efforts. The data underscores the importance of R&D in maintaining competitive advantage and driving future breakthroughs. As the pharmaceutical landscape continues to evolve, these investments will play a pivotal role in shaping the industry's future.
Who Prioritizes Innovation? R&D Spending Compared for Johnson & Johnson and Biogen Inc.
Johnson & Johnson or Arrowhead Pharmaceuticals, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Bristol-Myers Squibb Company and Catalyst Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: GSK plc and Catalyst Pharmaceuticals, Inc.
Research and Development Investment: argenx SE vs Catalyst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Lantheus Holdings, Inc. and Catalyst Pharmaceuticals, Inc.
TG Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Verona Pharma plc and Catalyst Pharmaceuticals, Inc.
R&D Spending Showdown: Catalyst Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
R&D Insights: How Catalyst Pharmaceuticals, Inc. and MannKind Corporation Allocate Funds
Catalyst Pharmaceuticals, Inc. or Dynavax Technologies Corporation: Who Invests More in Innovation?